Bridging solubility between drug discovery and development.

Solubility has a crucial role in the success of a drug candidate. Compounds with low solubility not only cause problems for in vitro and in vivo assays, but also add significant burdens to drug development. Drug discovery and drug development often have different solubility screening requirements and methodologies have been developed to meet the needs of these different stages.

[1]  M. Waring.  Lipophilicity in drug discovery , 2010, Expert Opinion on Drug Discovery.

[2]  Manfred Kansy,et al.  High throughput solubility measurement in drug discovery and development. , 2007, Advanced drug delivery reviews.

[3]  Michael J Hageman.  Preformulation designed to enable discovery and assess developability. , 2010, Combinatorial chemistry & high throughput screening.

[4]  W. Curatolo,et al.  Physical chemical properties of oral drug candidates in the discovery and exploratory development settings , 1998 .

[5]  S. Venkatesh,et al.  Role of the development scientist in compound lead selection and optimization. , 2000, Journal of pharmaceutical sciences.

[6]  S. Benita.  Self-Emulsifying Oral Lipid-Based Formulations for Improved Delivery of Lipophilic Drugs , 2005 .

[7]  Jeremy R Everett,et al.  NanoStore: A Concept for Logistical Improvements of Compound Handling in High-Throughput Screening , 2005, Journal of biomolecular screening.

[8]  V. Stella,et al.  Prodrug strategies to overcome poor water solubility. , 2007, Advanced drug delivery reviews.

[9]  Kiyohiko Sugano,et al.  High throughput solubility measurement with automated polarized light microscopy analysis. , 2006, Journal of pharmaceutical sciences.

[10]  N. Meanwell.  The Emerging Utility of Co-Crystals in Drug Discovery and Development , 2008 .

[11]  S. Davis,et al.  Physiological Factors in Drug Absorption , 1991, Annals of the New York Academy of Sciences.

[12]  D. T. Friesen,et al.  Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. , 2008, Molecular pharmaceutics.

[13]  S. Badawy,et al.  Formulation of Solid Dosage Forms to Overcome Gastric pH Interaction of the Factor Xa Inhibitor, BMS-561389 , 2006, Pharmaceutical Research.

[14]  Brian Samas,et al.  An intravenous formulation decision tree for discovery compound formulation development. , 2003, International journal of pharmaceutics.

[15]  Kiyohiko Sugano,et al.  Theoretical dissolution model of poly-disperse drug particles in biorelevant media. , 2008, Journal of pharmaceutical sciences.

[16]  Andrew G. Leach,et al.  Matched molecular pairs as a guide in the optimization of pharmaceutical properties; a study of aqueous solubility, plasma protein binding and oral exposure. , 2006, Journal of medicinal chemistry.

[17]  J. Swarbrick,et al.  Encyclopedia of Pharmaceutical Technology , 2006 .

[18]  A. Bansal,et al.  Impact of Solid-State Properties on Lubrication Efficacy of Magnesium Stearate , 2005, Pharmaceutical development and technology.

[19]  Ping Li,et al.  Developing early formulations: practice and perspective. , 2007, International journal of pharmaceutics.

[20]  Jennifer B Dressman,et al.  Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[21]  R. Strickley.  Solubilizing Excipients in Oral and Injectable Formulations , 2004, Pharmaceutical Research.

[22]  V. Jordan,et al.  Tamoxifen: a most unlikely pioneering medicine , 2003, Nature Reviews Drug Discovery.

[23]  K. Raghavan,et al.  Predicting Effect of Food on Extent of Drug Absorption Based on Physicochemical Properties , 2007, Pharmaceutical Research.

[24]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[25]  Hannah M. Jones,et al.  Modelling and PBPK Simulation in Drug Discovery , 2009, The AAPS Journal.

[26]  S. Byrn,et al.  A solid-state approach to enable early development compounds: selection and animal bioavailability studies of an itraconazole amorphous solid dispersion. , 2010, Journal of pharmaceutical sciences.

[27]  Karen A. Dehring,et al.  Automated robotic liquid handling/laser-based nephelometry system for high throughput measurement of kinetic aqueous solubility. , 2004, Journal of pharmaceutical and biomedical analysis.

[28]  Xue-Qing Chen,et al.  Discovery pharmaceutics—Challenges and opportunities , 2006, The AAPS Journal.

[29]  D. Fleisher,et al.  Drug, Meal and Formulation Interactions Influencing Drug Absorption After Oral Administration , 1999, Clinical pharmacokinetics.

[30]  W. Tong,et al.  Impact of solid state properties on developability assessment of drug candidates. , 2004, Advanced drug delivery reviews.

[31]  C Nicholas Hodge,et al.  Streamlined system for purifying and quantifying a diverse library of compounds and the effect of compound concentration measurements on the accurate interpretation of biological assay results. , 2004, Analytical chemistry.

[32]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[33]  Aeri Park,et al.  Use of a Glutaric Acid Cocrystal to Improve Oral Bioavailability of a Low Solubility API , 2006, Pharmaceutical Research.

[34]  Kevin C. Johnson,et al.  Guidance in the Setting of Drug Particle Size Specifications to Minimize Variability in Absorption , 1996, Pharmaceutical Research.

[35]  Minoru Ishikawa,et al.  Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry. , 2011, Journal of medicinal chemistry.

[36]  W. L. Jorgensen,et al.  Prediction of drug solubility from structure. , 2002, Advanced drug delivery reviews.

[37]  L. Di,et al.  Solubility Issues in Early Discovery and HTS , 2007 .

[38]  G. Ferron,et al.  The Effect of a High‐Fat Meal on the Oral Bioavailability of the Immunosuppressant Sirolimus (Rapamycin) , 1999, Journal of clinical pharmacology.

[39]  C. Bevan,et al.  A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. , 2000, Analytical chemistry.

[40]  Thierry Lavé,et al.  Predicting Pharmacokinetic Food Effects Using Biorelevant Solubility Media and Physiologically Based Modelling , 2006, Clinical pharmacokinetics.

[41]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[42]  György M Keseru,et al.  Hit discovery and hit-to-lead approaches. , 2006, Drug discovery today.

[43]  M. Evans,et al.  Improvement of physiochemical properties of the tetrahydroazepinoindole series of farnesoid X receptor (FXR) agonists: beneficial modulation of lipids in primates. , 2010, Journal of medicinal chemistry.

[44]  Georges Houin,et al.  Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. , 2004, International journal of pharmaceutics.

[45]  Ning Shan,et al.  The role of cocrystals in pharmaceutical science. , 2008, Drug discovery today.

[46]  B. Testa,et al.  Lessons learned from marketed and investigational prodrugs. , 2004, Journal of medicinal chemistry.

[47]  M. S. Ku.  Preformulation Consideration for Drugs in Oral CR Formulation , 2010 .

[48]  Edward H. Kerns,et al.  Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization , 2008 .

[49]  Kiyohiko Sugano,et al.  Introduction to computational oral absorption simulation. , 2009, Expert opinion on drug metabolism & toxicology.

[50]  M. Brewster,et al.  Solvent systems and their selection in pharmaceutics and biopharmaceutics , 2007 .

[51]  Kiyohiko Sugano,et al.  Prediction of food effect by bile micelles on oral drug absorption considering free fraction in intestinal fluid. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[52]  E. Kwong,et al.  Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates. , 2010, Journal of medicinal chemistry.

[53]  E. F. Fiese,et al.  General pharmaceutics--the new physical pharmacy. , 2003, Journal of pharmaceutical sciences.

[54]  David J W Grant,et al.  Identifying the Stable Polymorph Early in the Drug Discovery–Development Process , 2005, Pharmaceutical development and technology.

[56]  Liping Zhou,et al.  Development of a high throughput equilibrium solubility assay using miniaturized shake-flask method in early drug discovery. , 2007, Journal of pharmaceutical sciences.

[57]  Jennifer B Dressman,et al.  Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange Book database. , 2007, Journal of medicinal chemistry.

[58]  Jun-Shik Choi,et al.  Enhanced bioavailability of piroxicam via salt formation with ethanolamines. , 2005, International journal of pharmaceutics.

[59]  Thilo A Fligge,et al.  Integration of a rapid automated solubility classification into early validation of hits obtained by high throughput screening. , 2006, Journal of pharmaceutical and biomedical analysis.

[60]  Bruno C. Hancock,et al.  What is the True Solubility Advantage for Amorphous Pharmaceuticals? , 2000, Pharmaceutical Research.

[61]  L. Di,et al.  High throughput microsomal stability assay for insoluble compounds. , 2006, International journal of pharmaceutics.

[62]  T. Mano,et al.  Solubility and dissolution profile assessment in drug discovery. , 2007, Drug metabolism and pharmacokinetics.

[63]  Vinod P. Shah,et al.  Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions , 2002, Pharmaceutical Research.

[64]  Li Di,et al.  Drug-like property concepts in pharmaceutical design. , 2009, Current pharmaceutical design.

[65]  Gérard Hopfgartner,et al.  P‐Glycoprotein and Surfactants: Effect on Intestinal Talinolol Absorption , 2005, Clinical pharmacology and therapeutics.

[66]  J. Arrowsmith,et al.  Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents. , 1986, Journal of medicinal chemistry.

[67]  W. Löscher,et al.  New Injectable Aqueous Carbamazepine Solution Through Complexing with 2‐Hydroxypropyl‐β‐Cyclodextrin: Tolerability and Pharmacokinetics After Intravenous Injection in Comparison to a Glycofurol‐Based Formulation , 1995, Epilepsia.

[68]  Filippos Kesisoglou,et al.  Nanosizing--oral formulation development and biopharmaceutical evaluation. , 2007, Advanced drug delivery reviews.

[69]  R. Saito,et al.  Quantitative analysis of the effect of supersaturation on in vivo drug absorption. , 2010, Molecular pharmaceutics.

[70]  Tycho Heimbach,et al.  Prodrugs: design and clinical applications , 2008, Nature Reviews Drug Discovery.

[71]  Stephen R. Johnson,et al.  A computational model for the prediction of aqueous solubility that includes crystal packing, intrinsic solubility, and ionization effects. , 2007, Molecular pharmaceutics.

[72]  Li Di,et al.  Biological assay challenges from compound solubility: strategies for bioassay optimization. , 2006, Drug discovery today.

[73]  Li Di,et al.  Application of pharmaceutical profiling assays for optimization of drug-like properties. , 2005, Current opinion in drug discovery & development.

[74]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[75]  H. Fung,et al.  Effect of organic cosolvent-induced skeletal muscle damage on the bioavailability of intramuscular [14C]diazepam. , 1990, Journal of pharmaceutical sciences.

[76]  Abu T M Serajuddin,et al.  Trends in solubility of polymorphs. , 2005, Journal of pharmaceutical sciences.

[77]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[78]  P. Ertl,et al.  Computational approaches to determine drug solubility. , 2007, Advanced drug delivery reviews.

[79]  L. Di,et al.  In vitro solubility assays in drug discovery. , 2008, Current drug metabolism.